- Home
- CMPO vs VCYT Comparison
CMPO vs VCYT Comparison
Compare CMPO & VCYT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CMPO | VCYT |
|---|---|---|
| Founded | 2000 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.9B |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | CMPO | VCYT |
|---|---|---|
| Price | $20.39 | $47.39 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 9 |
| Target Price | $25.50 | ★ $44.44 |
| AVG Volume (30 Days) | 938.8K | ★ 995.1K |
| Earning Date | 11-03-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.38 |
| Revenue | $160,683,000.00 | ★ $495,141,000.00 |
| Revenue This Year | $12.53 | $16.02 |
| Revenue Next Year | $9.95 | $10.74 |
| P/E Ratio | ★ N/A | $123.92 |
| Revenue Growth | N/A | ★ 16.41 |
| 52 Week Low | $9.24 | $22.61 |
| 52 Week High | $26.78 | $50.71 |
Technical Indicators
Market Signals| Indicator | CMPO | VCYT |
|---|---|---|
| Relative Strength Index (RSI) | 54.82 | 65.13 |
| Support Level | $19.26 | $45.68 |
| Resistance Level | $20.30 | $48.10 |
| Average True Range (ATR) | 0.87 | 2.03 |
| MACD | 0.09 | 0.24 |
| Stochastic Oscillator | 89.48 | 74.23 |
Price Performance
Historical ComparisonAbout CMPO CompoSecure Inc.
CompoSecure Inc is engaged in designing and manufacturing premium financial cards. The Company's metal payment card technology and Arculus security and authentication capabilities deliver premium branded experiences which enable people to access and use their assets, and ensure trust at the point of a transaction. Its products include Metal Cards and Arculus, a digital security platform. It has two reportable segments: Payment Card and Arculus.
About VCYT Veracyte Inc.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.